Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.
Study Type
OBSERVATIONAL
Enrollment
200
No intervention
West China Hospital
Chengdu, Sichuan, China
mortality
death
Time frame: 30 days
Cure Rate
clinical and microbiological effectiveness
Time frame: 30 days
Number of participants with treatment-related adverse events
organ dysfunction，allergy，creatine kinase levels，eosinophilic pneumonia，etc.
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.